Table 3.
Univariate |
Multivariate |
|||
P value | RR (95%CI) | P value | RR (95%CI) | |
Sex | 0.001 | 10.262 (2.479-42.481) | < 0.001 | 47.505 (7.384-305.601) |
Age | 0.198 | 0.968 (0.921-1.017) | ||
Stage | 0.082 | 2.106 (0.911-4.871) | ||
BCLC | 0.441 | 1.257 (0.702-2.250) | ||
Size | 0.903 | 1.007 (0.904-1.121) | ||
PVT | 0.247 | 1.741 (0.681-4.452) | ||
LN metastasis | 0.408 | 1.867 (0.425-8.191) | ||
Multiplicity | 0.944 | 1.033 (0.412-2.591) | ||
AFP | 0.653 | 0.999 (0.996-1.002) | ||
PIVKA-II | 0.889 | 0.996 (0.947-1.048) | ||
Pre-RT treatment | 0.290 | 1.627 (0.660-4.013) | ||
Baseline IL-1 | 0.895 | 0.997 (0.955-1.041) | ||
Baseline IL-6 | 0.000 | 1.011 (1.005-1.018) | < 0.001 | 1.019 (1.011-1.028) |
Baseline IL-8 | 0.985 | 1.000 (0.997-1.003) | ||
Baseline IL-10 | 0.437 | 1.060 (0.915-1.227) | ||
Baseline IL-12 | 0.903 | 0.996 (0.938-1.059) | ||
Baseline TNF-α | 0.864 | 0.993 (0.918-1.074) |
Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.